Can bone markers guide more effective treatment of bone metastases from breast cancer?

Breast Cancer Research and Treatment

Volumn 97, Issue 1, 2006, Pages 81-90

  Clemons, Mark ^a   Cole, David E C ^a   Gainford, Mary C ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; C telopeptide; N telopeptide

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PROTEIN; SIALOPROTEIN; TRAP5B PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; HUMAN; MORBIDITY; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SKELETAL RELATED EVENT; TREATMENT OUTCOME;

BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN TYPE I; FEMALE; HUMANS; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 33646738225     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9094-7     Document Type: Review

References (66)

1. Coleman RE: Skeletal complications of malignancy. Cancer 80: 1588-1594, 1997
2. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G: Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastases. Breast Cancer Res Treat 59: 271-278, 2000
3. James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, Robertson JF: Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. Br J Cancer 89: 660-665, 2003
4. Rubens RD: Bone metastases - the clinical problem. Eur J Cancer 34: 210-213, 1998
5. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66, 1987
6. Hill ME, Richards MA, Gregory WM, Smith P, Rubens RD: Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer 68: 969-973, 1993
7. Clemons M: Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support. Clin Oncol (R Coll Radiol) 16: 108-111, 2004
8. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335: 1785-1791, 1996
9. Theriault R, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidronate reduces the skeletal morbidity rate in women with advanced breast cancer and lytic bone lesions: a randomized controlled study. J Clin Oncol 17: 846-854, 1999
10. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - long term follow up of two randomized controlled trials. Cancer 88: 1082-1090, 2000
11. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B: MF 4265 Study Group: intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399-1405, 2003
12. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377-387, 2001
13. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Lino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized placebo controlled clinical trial. J Clin Oncol 23: 3314-3321, 2005
14. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M: On behalf of the MF 4434 Study Group: oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double blind, placebo-controlled trial. Ann Oncol 15: 743-750, 2004
15. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo- controlled phase III studies. Br J Cancer 90: 1133-1137, 2004
16. Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E: Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88: 701-707, 2001
17. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT: Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246: 67-74, 1999
18. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65, 1993
19. Gainford MC, Dranitsaris G, Clemons M: Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 330: 769-773, 2005
20. Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, Kee-Cresswell D, Chang J, Yogendran G, Trudeau M, De Angelis C, Cottrell W, Dranitsaris G: Do physicians follow systemic treatment and funding policy guidelines?. Can J Clin Pharmacol 11: e168-e178, 2004
21. Clamp A, Danson S, Nguyen H, Cole D, Clemons M: Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 5: 607-616, 2004
22. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT: Bone imaging in metastatic breast cancer. J Clin Oncol 22: 2942-2953, 2004
23. Cheung KL, Graves CR, Robertson JF: Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26: 91-102, 2000
24. Fohr B, Dunstan CR, Siebel MJ: Clinical Review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 88: 5059-5075, 2003
25. Rodan G: The development and function of the skeleton and bone metastases. Cancer 97: 726-732, 2003
26. Roodman G: Mechanisms of bone metastases. N Engl J Med 350: 1655-1664, 2004
27. Gainford MC, Dranitsaris G, Clemons M: Systemic treatment of bone metastases from breast cancer. Is it all that it is cracked up to be?. J Clin Oncol 23: 4802-4803, 2005
28. Swaminathan R: Biochemical markers of bone turnover. Clin Chim Acta 313: 95-105, 2001
29. Deniers L: Bone markers in the management of patients with skeletal metastases. Cancer 97(suppl 3): 874-879, 2003
30. Bernardi D, Zaninotto M, Plebani M: Requirements for improving quality in the measurement of bone markers. Clin Chim Acta 346: 79-86, 2004
31. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A: Prospective evaluation of the peptide bound collagen type 1 cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850-856, 2002
32. Wada N, Fujisaki M, Ishii S, Ikeda T, Kitajima M: Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 8: 131-137, 2001
33. Coleman RE: The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94: 2521-2533, 2002
34. Capeller B, Caffier H, Sutterlin MW, Dietl J: Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 23: 1011-1015, 2003
35. Luftner D, Gunther S, Flath B, Muller C, Echteroff K, Mergenthaler HG, Wernecke KD, Possinger K: The course of the urinary DPD-cross-link secretion in metastatic breast cancer - a possibility for response assessment. Anticancer Res 19: 2537-2544, 1999
36. Bombardieri E, Martinetti A, Miceli R, Miriani L, Castellani MR, Seregni E: Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?. Eur J Nucl Med 24: 1349-1355, 1997
37. Hou MF, Lin SB, Yuan SS, Tsai LY, Tsai SM, Hseih JS, Huang TJ: Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients. Ann Clin Lab Sci 33: 55-61, 2003
38. Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, Wildiers J, Michel J, Leonard R, Nortier J, Mignolet F, Ford J: Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 80: 221-228, 1999
39. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R: Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34: 2021-2026, 1998
40. Lipton A, Costa L, Ali SM, Demers LM: Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27: 181-185, 2001
41. Lipton A, Costa L, Ali S, Demers L: Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28: 54-59, 2001
42. Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE: Relationship between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8: 1243-1250, 1997
43. Body JJ, Dumon JC, Gineyts E, Delmas PD: Comparative evaluation of markers of bone resorption in patients with breast-cancer induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75: 408-412, 1997
44. Coleman RE, Major P, Lipton A, Brown J, Lee K, Smith M, Saad F, Zheng M, Hei J, Saeman J, Cook R: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925-4935, 2005
45. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE: Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031-2037, 2003
46. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors. J Natl Cancer Inst 97: 59-69, 2005
47. Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J, Lipton A: Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastases. Ann Oncol 15: 455-459, 2004
48. Jagdev SP, Purohit OP, Heatley S, Herling C, Coleman RE: Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12: 1433-1438, 2001
49. Brown JE, Ellis SP, Gutcher SA, Purohit OP, Turner L, Neville-Webbe HL, Coleman RE: Using bone turnover markers to direct bisphosphonate therapy: is this a feasible approach?. Cancer Treat Rev 31: S30-(abs 50), 2005
50. Coleman RE, Purohit OP, Black C, Vinholes JJF, Schlosser K, Huss H, Quinn KJ, Kanis J: Double blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 10: 311-316, 1999
51. Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A: A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7: 478-485, 2001
52. Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift R, Conde F, Von Teichert JM: A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91: 144-154, 2001
53. Brown JE, Coleman RE: Assessment of the effects of breast cancer on bone and the response to therapy. Breast 11: 375-385, 2002
54. Diel IJ, Marschner N, Kindler M, Lange O, Untch M, Hurtz HJ, et al. Continuous oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases. Proc Am Soc Clin Oncol 18: (abs 488), 1999
55. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91: 1191-1200, 2001
56. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100: 36-43, 2004
57. Body JJ, Lichinitser M, Tjulandin SA, Budde M, Bergström B: Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial. Proc Am Soc Clin Oncol 23: (abstract 534), 2005
58. Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M: Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian medical oncologists. Support Care Cancer 12: 852-858, 2004
59. Roodman GD: High bone turnover markers predict por outcome in patients with bone metastases. J Clin Oncol 23: 4821-4822, 2005
60. Hillner BE, Weeks JC, Desch CE, Smith TJ: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost effectiveness analysis. J Clin Oncol 18: 72-79, 2000
61. Body JJ: Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97: 859-865, 2003
62. Martinetti A, Seregni E, Ripamonti C, Ferari L, De Conno F, Miceli R, Pallotti F, Coliva A, Biancolini D, Bombardieri E: Serum, levels of tartrate resistant acid phosphatase 5b in breast cancer patients treated with pamidronate. Int J Biol Markers 17: 253-258, 2002
63. Demers L: Bone markers in the management of patients with skeletal metastases. Cancer 97(suppl 3): 874-879, 2003
64. Lipton A, Ali S, Leitzel K, Chinchilli V, Witters L, Engle L, Hollaway D, Bekker P, Dunstan CR: Serum osteoprotegrin levels in healthy controls and cancer patients. Clin Cancer Res 8: 2306-2310, 2002
65. Diel I, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster F, Bastert G: Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastases. Clin Cancer Res 5: 3914-3919, 1999
66. Seibel M, Woitge H, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster F, Ziegler R: Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81: 3289-3294, 1996